If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-22. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Resonance ionization is a process in optical physics used to excite a specific atom (or molecule) beyond its ionization potential to form an ion using a beam of photons irradiated from a pulsed laser light. In resonance ionization, the absorption or emission properties of the emitted photons are not considered, rather only the resulting excited ions are mass-selected, detected and measured. Depending on the laser light source used, one electron can be removed from each atom so that resonance ionization produces an efficient selectivity in two ways: elemental selectivity in ionization and isotopic selectivity in measurement. During resonance ionization, an ion gun or desorption laser creates a cloud of atoms and molecules from a solid surface or gas-phase sample before a tunable laser is used to fire a beam of photons at the cloud of particles emanating from the sample (analyte). An initial photon from this beam is absorbed by one of the sample atoms, exciting one of the atom's electrons to an intermediate excited state. A second photon then ionizes the same atom from the intermediate state such that its high energy level causes it to be ejected from its orbital; the result is a packet of positively charged ions which are then delivered to a mass analyzer. Resonance ionization contrasts with resonance-enhanced multiphoton ionization (REMPI) in that the latter is neither selective nor efficient since resonances are seldom used to prevent interference. Also, resonance ionization is used for an atomic (elemental) analyte, whereas REMPI is used for a molecular analyte.
== Criticism == Criticism of cold fusion claims generally take one of two forms: either pointing out the theoretical implausibility that fusion reactions have occurred in electrolysis setups or criticizing the excess heat measurements as being spurious, erroneous, or due to poor methodology or controls. There are several reasons why known fusion reactions are an unlikely explanation for the excess heat and associated cold fusion claims.
== Plot == Mumbai Police Commissioner Aditya Arunachalam kills gangsters in the city in police encounters. His behaviour received widespread condemnation, and the National Human Rights Commission of India decided to act against him. One of the panellists on the commission, a former friend of Aditya, discovers the murder of his daughter Valli sparked his killing spree. Past: A minister assigns Aditya to Mumbai as the new Commissioner to curb the rampant drug trafficking and prostitution in the city. Upon arriving in Mumbai, he rescues three kidnapped women, one of whom is the daughter of the Deputy Chief Minister of Maharashtra. Sensing an opportunity, Aditya uses the kidnapped women as an excuse to initiate a campaign against the city's drug trafficking and prostitution rings. His efforts are highly successful; the police arrest numerous drug dealers and child traffickers. Among the arrested is Ajay Malhotra, the son of influential industrialist Vinod Malhotra, who attempts to bail out Ajay, but Aditya refuses bail. Aditya, seeking Ajay's testimony on his involvement in drug smuggling, visits him in prison and discovers a proxy in his place. He asks the state and central governments to investigate and discovers the officials assigned to Ajay's case work for Vinod. Through a covert investigation, Aditya learns Ajay is hiding in Bangkok and has the Royal Thai Police arrest him on passport fraud charges. Corrupt diplomats on Vinod's payroll falsely declare Ajay imprisoned in India, which leads to his release from Thai custody.
== Ecology == Several animals such as wild boar, deer, squirrels, and ants have been recorded as contributing to the survival of buds and possibly assisting dispersal through their activities on the forest floor.
Many of the chloroplast's protein complexes consist of subunits from both the chloroplast genome and the host's nuclear genome. As a result, protein synthesis must be coordinated between the chloroplast and the nucleus. The chloroplast is mostly under nuclear control, though chloroplasts can also give out signals regulating gene expression in the nucleus, called retrograde signaling. Recent research indicates that parts of the retrograde signaling network once considered characteristic for land plants emerged already in an algal progenitor, integrating into co-expressed cohorts of genes in the closest algal relatives of land plants.
Sources: en.wikipedia.org
Under the style and title: ANCIENT ORDER OF ORIENTAL TEMPLARS, an organization, formerly known as: "The Hermetic Brotherhood of Light", has been reorganized and reconstituted. This reconstituted association is an international organization, and is hereinafter referred to as the O.T.O.
A study of iron-deficiency among early Mongolian nomads showed that although overall rates of cribra orbitalia declined from 28.7 percent (27.8 percent of the total female population, 28.4 percent of the total male population, 75 percent of the total juvenile population) during the Bronze and Iron Ages, to 15.5 percent during the Hunnu (2209–1907 BP) period, the rate of females with cribra orbitalia remained roughly the same, while incidence among males and children declined (29.4 percent of the total female population, 5.3 percent of the total male population, and 25 percent of the juvenile population had cribra orbitalia). This study hypothesized that adults may have lower rates of cribra orbitalia than juveniles because lesions either heal with age or lead to death. Higher rates of cribia orbitalia among females may indicate lesser health status, or greater survival of young females with cribia orbitalia into adulthood.
=== Medicaid overbilling === A fraud investigation by the United States Department of Justice began in 2000 when allegations were brought in two separate lawsuits filed by whistleblowers under the False Claims Act. They alleged that Merck failed to pay proper rebates to Medicaid and other health care programs and paid illegal remuneration to health care providers. On February 7, 2008, Merck agreed to pay more than $650 million to settle charges that it routinely overbilled Medicaid for its most popular medicines. The settlement was one of the largest pharmaceutical settlements in history. The federal government received more than $360 million, plus 49 states and Washington, DC, received over $290 million. One whistleblower received a $68 million reward. Merck made the settlement without an admission of liability or wrongdoing.
== Treatment eligibility == Many providers use informed consent, whereby someone seeking hormone therapy can sign a statement of informed consent and begin treatment without much gatekeeping. For other providers, eligibility is determined using major diagnostic tools such as ICD-11 or the Diagnostic and Statistical Manual of Mental Disorders (DSM) to classify a patient with gender dysphoria. The Endocrine Society requires physicians that diagnose gender dysphoria and gender incongruence to be trained in psychiatric disorders with competency in ICD-11 and DSM-5. The healthcare provider should also obtain a thorough assessment of the patient's mental health and identify potential psychosocial factors that can affect therapy.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.